Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.
Standard
Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. / Tilki, Derya; Shariat, Shahrokh F; Lotan, Yair; Rink, Michael; Karakiewicz, Pierre I; Schoenberg, Mark P; Lerner, Seth P; Sonpavde, Guru; Sagalowsky, Arthur I; Gupta, Amit.
in: BJU INT, Jahrgang 111, Nr. 8, 8, 2013, S. 1215-1221.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.
AU - Tilki, Derya
AU - Shariat, Shahrokh F
AU - Lotan, Yair
AU - Rink, Michael
AU - Karakiewicz, Pierre I
AU - Schoenberg, Mark P
AU - Lerner, Seth P
AU - Sonpavde, Guru
AU - Sagalowsky, Arthur I
AU - Gupta, Amit
N1 - © 2012 BJU International.
PY - 2013
Y1 - 2013
N2 - OBJECTIVE: To determine the outcomes of patients with final pathological stage T1N0 disease after radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) and to determine whether lymphovascular invasion (LVI) is an independent predictor of prognosis in these patients.PATIENTS AND METHODS: Records of 958 consecutive patients who underwent RC at three academic centres were reviewed. A total of 101 patients with negative lymph nodes and with final stage (the higher of the pre-RC clinical/transurethral resection [TUR] and post-RC pathological stages) T1 UCB were identified. The median (range) follow-up was 38 (0.4-177) months and the median (range) number of nodes examined was 19 (9-80).RESULTS: Overall, 12/101 (11.9%) patients experienced cancer recurrence and 7/101 (6.9%) died from their cancer. The 3-year recurrence-free survival probability (SD) was 0.89 (0.04) and 3-year cancer-specific survival probability (SD) was 0.96 (0.02). Six of 101 (6%) patients had LVI, of whom four experienced disease recurrence and three died from bladder cancer. All recurrences and deaths occurred in patients who had either LVI and/or concomitant carcinoma in situ. On multivariable analysis, LVI (hazard ratio [HR] 4.9, P = 0.01) and higher pathological stage (HR 8.5, P = 0.04) predicted cancer recurrence and LVI (HR 6.7, P = 0.01) predicted cancer-specific survival.CONCLUSIONS: LVI helps identify patients with final pathological T1N0 UCB who are at significantly increased risk of bladder cancer recurrence and death. These patients should be considered for close monitoring after cystectomy.
AB - OBJECTIVE: To determine the outcomes of patients with final pathological stage T1N0 disease after radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) and to determine whether lymphovascular invasion (LVI) is an independent predictor of prognosis in these patients.PATIENTS AND METHODS: Records of 958 consecutive patients who underwent RC at three academic centres were reviewed. A total of 101 patients with negative lymph nodes and with final stage (the higher of the pre-RC clinical/transurethral resection [TUR] and post-RC pathological stages) T1 UCB were identified. The median (range) follow-up was 38 (0.4-177) months and the median (range) number of nodes examined was 19 (9-80).RESULTS: Overall, 12/101 (11.9%) patients experienced cancer recurrence and 7/101 (6.9%) died from their cancer. The 3-year recurrence-free survival probability (SD) was 0.89 (0.04) and 3-year cancer-specific survival probability (SD) was 0.96 (0.02). Six of 101 (6%) patients had LVI, of whom four experienced disease recurrence and three died from bladder cancer. All recurrences and deaths occurred in patients who had either LVI and/or concomitant carcinoma in situ. On multivariable analysis, LVI (hazard ratio [HR] 4.9, P = 0.01) and higher pathological stage (HR 8.5, P = 0.04) predicted cancer recurrence and LVI (HR 6.7, P = 0.01) predicted cancer-specific survival.CONCLUSIONS: LVI helps identify patients with final pathological T1N0 UCB who are at significantly increased risk of bladder cancer recurrence and death. These patients should be considered for close monitoring after cystectomy.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Carcinoma, Transitional Cell
KW - Cystectomy
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Incidence
KW - Lymph Nodes
KW - Lymphatic Metastasis
KW - Male
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Neoplasm Staging
KW - Probability
KW - Prognosis
KW - Retrospective Studies
KW - Survival Rate
KW - United States
KW - Urinary Bladder Neoplasms
U2 - 10.1111/j.1464-410X.2012.11455.x
DO - 10.1111/j.1464-410X.2012.11455.x
M3 - SCORING: Journal article
C2 - 23181623
VL - 111
SP - 1215
EP - 1221
JO - BJU INT
JF - BJU INT
SN - 1464-4096
IS - 8
M1 - 8
ER -